{"uid":"cap_GC5-K-e4vjf8b-oXGiCA_","slug":"clinicalintelpulse-disease-landscape-lite-82f699c4","name":"ClinicalIntelPulse Disease Landscape Lite","description":"Deterministic preview of the disease pipeline landscape — Phase 2/3 trial counts, sponsor rollup, trial-status breakdown and a sample of trials straight off ClinicalTrials.gov. No LLM synthesis. For agents with small per-call budgets; upgrade to disease-landscape for approved drugs, mechanism gaps, PDUFA calendar, deal activity and an opportunity score.","url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/disease-landscape-lite","method":"GET","headers":{},"bodySchema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET","HEAD","DELETE"],"type":"string"},"queryParams":{"type":"object","properties":{"condition":{"type":"string"}}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"errors":{"type":"object","description":"Documented error responses, keyed by HTTP status code","additionalProperties":{"type":"object","required":["description"],"properties":{"example":{"type":"object"},"description":{"type":"string"}}}},"example":{"type":"object"}}}}},"responseSchema":{"type":"json","example":{"upsell":{"adds":"Approved drugs, mechanism-of-action landscape (crowded/emerging/gaps), PDUFA calendar, M&A deal activity, investment thesis, 0-100 opportunity score.","price_usd":0.35,"full_product":"/api/clinical/disease-landscape"},"top_sponsors":[{"sponsor":"Novo Nordisk A/S","trial_count":6,"sponsor_class":"INDUSTRY"}],"deterministic":true,"query_summary":{"as_of":"2026-07-25","condition":"NASH (Nonalcoholic Steatohepatitis)"},"top_countries":[{"country":"United States","trial_count":40}],"status_breakdown":{"COMPLETED":14,"RECRUITING":31,"ACTIVE_NOT_RECRUITING":22},"pipeline_overview":{"phase2_count":48,"phase3_count":19,"total_active":67,"completed_total":210},"sample_phase3_trials":[{"nctId":"NCT04858633","title":"Semaglutide in NASH","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S"}]}},"example":null,"exampleRequest":null,"tags":["x402"],"displayCostAmount":"0.25","displayCostAsset":"USDC","priceDynamic":false,"priceHint":null,"priceStatus":"priced","priceSource":"probe","requiresHandshake":false,"reviewCount":0,"rating":{"score":"0.00","successRate":"0.00","reviews":0,"stars":null,"state":"unrated"},"availabilityStatus":"unknown","priceObserved":null,"sessionDeposit":null,"pricing":{"kind":"static","summary":"$0.25/call","primary":{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.25","per":"call","confidence":"exact"},"accepted":[{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.25","per":"call","confidence":"exact"}]},"paymentMethods":[{"uid":"pm_BBkL3UDdnzVGQ98wO-VIQ","protocol":"x402","methodType":"crypto","chain":"base","mode":"charge","costAmount":"0.25","costPer":"request","priority":0,"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","unit":"request","depositMicros":null,"planRef":null}],"brandName":null,"brandSlug":null,"brandBaseUrl":null,"brandDocsUrl":null,"whatItDoes":"Returns a deterministic preview of the clinical trial pipeline for a disease — Phase 2/3 trial counts, sponsor rollup, trial-status breakdown, and a sample of trials from ClinicalTrials.gov — with no LLM synthesis.","exampleAgentPrompt":"Give me a quick pipeline snapshot for non-small cell lung cancer — how many Phase 2 and Phase 3 trials are running, who the top sponsors are, and a sample of the trials from ClinicalTrials.gov.","exampleUseCases":[{"title":"Pipeline crowding check before entering indication","prompt":"How crowded is the NASH drug pipeline? Give me a Phase 2/3 trial count, a sponsor rollup, and a sample of active trials so I can gauge competition before we commit to the indication."},{"title":"Investor briefing on oncology indication","prompt":"I'm prepping a quick brief on the glioblastoma clinical trial landscape — can you pull the Phase 2 and Phase 3 trial counts, top sponsors, and trial-status breakdown for me?"},{"title":"Quick competitive scan for rare disease","prompt":"Before our strategy call, pull me a lite pipeline overview for myelofibrosis — I need trial counts by phase, who the main sponsors are, and a few sample trials from ClinicalTrials.gov."}],"resultDescription":"Returns Phase 2 and Phase 3 trial counts for the queried disease, a rollup of sponsoring organizations, a breakdown of trial statuses (e.g. recruiting, active not recruiting, completed), and a curated sample of individual trial records sourced directly from ClinicalTrials.gov. No LLM-generated text is included; all data is deterministic and structured.","failureModes":["Disease name not recognized or too ambiguous — returns empty or minimal results","ClinicalTrials.gov data temporarily unavailable — may return stale or incomplete counts","Overly broad disease term (e.g. 'cancer') may return truncated or capped results","Rate limiting or payment failure via x402 protocol results in 402 response and no data"],"whenToPreferThis":"Choose this endpoint when you need a fast, low-cost ($0.25), deterministic snapshot of a disease's Phase 2/3 trial pipeline without LLM synthesis — ideal for competitive scans, investor briefs, or pipeline triage. Upgrade to the full disease-landscape endpoint when you also need approved drug lists, mechanism gaps, PDUFA calendar, deal activity, or an opportunity score.","instructions":null,"reviewSummary":null,"reviewSummaryHighlights":null,"reviewSummaryConcerns":null,"reviewSummaryGeneratedAt":null,"activationCount":0,"lastUsedAt":null,"lastSuccessfullyRanAt":null,"lastHealthCheckAt":"2026-09-14T12:47:25.937Z","isFirstParty":false}